Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 5097325, 8 pages
https://doi.org/10.1155/2018/5097325
Research Article

Circulating CD3+CD4+CD161+ Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma

1Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, Republic of Korea

Correspondence should be addressed to Chang-Ki Min; rk.ca.cilohtac@nimkc

Received 11 July 2017; Revised 14 September 2017; Accepted 4 December 2017; Published 1 January 2018

Academic Editor: Roberto Crocchiolo

Copyright © 2018 Sung-Eun Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Child, G. J. Morgan, and F. E. Davies, “High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma,” The New England Journal of Medicine, vol. 348, no. 19, pp. 1875–1883, 2003. View at Publisher · View at Google Scholar
  2. A. Palumbo, F. Cavallo, F. Gay et al., “Autologous transplantation and maintenance therapy in multiple myeloma,” The New England Journal of Medicine, vol. 371, no. 10, pp. 895–905, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. H. W. Auner, R. Szydlo, J. Hoek et al., “Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: Increased use and improved outcomes in elderly patients in recent years,” Bone Marrow Transplantation, vol. 50, no. 2, pp. 209–215, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. S. V. Rajkumar, “Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management,” American Journal of Hematology, vol. 91, no. 7, pp. 719–734, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Vera-Llonch, G. Oster, C. M. Ford, J. Lu, and S. Sonis, “Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma,” The Journal of Supportive Oncology, vol. 5, no. 5, pp. 231–235, 2007. View at Google Scholar · View at Scopus
  6. G. Reich, M. Y. Mapara, P. Reichardt, B. Dörken, and G. Maschmeyer, “Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: Comparison between patients with lymphoma or multiple myeloma and patients with solid tumors,” Bone Marrow Transplantation, vol. 27, no. 5, pp. 525–529, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. B. W. Teh, S. J. Harrison, M. Pellegrini, K. A. Thursky, L. J. Worth, and M. A. Slavin, “Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection,” Blood Reviews, vol. 28, no. 2, pp. 75–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. H. Spahn, W. Li, and D. Kreisel, “Innate immune cells in transplantation,” Current Opinion in Organ Transplantation, vol. 19, no. 1, pp. 14–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. T. W. Kim, S.-E. Lee, J.-Y. Lim et al., “Clinical significance of pre-transplant circulating CD3+CD4+CD161+ cell frequency on the occurrence of neutropenic infections after allogeneic stem cell transplantation,” Transplant Infectious Disease, vol. 19, no. 1, Article ID e12643, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. S.-E. Lee, S.-A. Yahng, B.-S. Cho et al., “Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma,” Cytotherapy, vol. 14, no. 4, pp. 505–512, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-E. Lee, J.-H. Yoon, S.-H. Shin et al., “Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma,” Annals of Hematology, vol. 93, no. 4, pp. 627–634, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Straka, M. Sandherr, H. Salwender et al., “Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy,” Blood, vol. 117, no. 7, pp. 2121–2128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Pizzo, D. Armstrong, G. Bodely et al., “From the immunocompromised host society: The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient,” The Journal of Infectious Diseases, vol. 161, no. 3, pp. 397–401, 1990. View at Publisher · View at Google Scholar · View at Scopus
  14. M. L. Sorror, M. B. Maris, and R. Storb, “Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT,” Blood, vol. 106, no. 8, pp. 2912–2919, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Attal, J.-L. Harousseau, A.-M. Stoppa et al., “A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma,” The New England Journal of Medicine, vol. 335, no. 2, pp. 91–97, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Giralt, E. A. Stadtmauer, J. L. Harousseau et al., “International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100),” Leukemia, vol. 23, no. 10, pp. 1904–1912, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Kumar, S. Galeb, and B. Djulbegovic, “Treatment of patients with multiple myeloma: An overview of systematic reviews,” Acta Haematologica, vol. 125, no. 1-2, pp. 8–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Cavo, P. Tacchetti, F. Patriarca et al., “Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study,” The Lancet, vol. 376, no. 9758, pp. 2075–2085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Moreau, H. Avet-Loiseau, T. Facon et al., “Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma,” Blood, vol. 118, no. 22, pp. 5752–5758, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Rosinol, A. Oriol, A. I. Teruel et al., “Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study,” Blood, vol. 120, no. 8, pp. 1589–1596, 2012. View at Google Scholar
  21. M. Attal, V. Lauwers-Cances, and G. Marit, “Lenalidomide maintenance after stem-cell transplantation for multiple myeloma,” The New England Journal of Medicine, vol. 366, no. 19, pp. 1782–1791, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Koreth, C. S. Cutler, B. Djulbegovic et al., “High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials,” Biology of Blood and Marrow Transplantation, vol. 13, no. 2, pp. 183–196, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. B. W. Teh, S. J. Harrison, L. J. Worth, T. Spelman, K. A. Thursky, and M. A. Slavin, “Risks, severity and timing of infections in patients with multiple myeloma: A longitudinal cohort study in the era of immunomodulatory drug therapy,” British Journal of Haematology, vol. 171, no. 1, pp. 100–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. K. H. G. Mills and J. C. Cawley, “Abnormal monoclonal antibody‐defined helper/suppressor T‐cell subpopulations in multiple myeloma: relationship to treatment and clinical stage,” British Journal of Haematology, vol. 53, no. 2, pp. 271–275, 1983. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Ogawara, H. Handa, T. Yamazaki et al., “High Th1/Th2 ratio in patients with multiple myeloma,” Leukemia Research, vol. 29, no. 2, pp. 135–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Peres-Andres, J. Almeida, M. Martin-Ayuso et al., “Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vβ repertoire,” Cancer, vol. 106, no. 6, pp. 1296–1305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. R. D. Brown, B. Pope, A. Murray et al., “Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10,” Blood, vol. 98, no. 10, pp. 2992–2998, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Jurisic, T. Srdic, G. Konjevic, O. Markovic, and M. Colovic, “Clinical stage-depending decrease of NK cell activity in multiple myeloma patients,” Medical Oncology, vol. 24, no. 3, pp. 312–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. G. Iliopoulou, M. V. Karamouzis, I. Missitzis et al., “Increased frequency of CD4+ cells expressing CD161 in cancer patients,” Clinical Cancer Research, vol. 12, no. 23, pp. 6901–6909, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S.-E. Lee, J.-Y. Lim, J.-H. Yoon et al., “CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease,” Biology of Blood and Marrow Transplantation, vol. 21, no. 3, pp. 421–428, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. S.-B. Woo, S. T. Sonis, M. M. Monopoli, and A. L. Sonis, “A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients,” Cancer, vol. 72, no. 5, pp. 1612–1617, 1993. View at Publisher · View at Google Scholar · View at Scopus
  32. J.-L. Pico, A. Avila-Garavito, and P. Naccache, “Mucositis: its occurrence, consequences, and treatment in the oncology setting,” The Oncologist, vol. 3, no. 6, pp. 446–451, 1998. View at Google Scholar · View at Scopus
  33. S. I. Bearman, F. R. Appelbaum, C. D. Buckner et al., “Regimen-related toxicity in patients undergoing bone marrow transplantation,” Journal of Clinical Oncology, vol. 6, no. 10, pp. 1562–1568, 1988. View at Publisher · View at Google Scholar · View at Scopus
  34. A. P. Rapoport, L. F. Miller Watelet, T. Linder et al., “Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants,” Journal of Clinical Oncology, vol. 17, no. 8, pp. 2446–2453, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Eilers, A. M. Berger, and M. C. Petersen, “Development, testing, and application of the oral assessment guide,” Oncol Nurs Forum, vol. 15, no. 3, pp. 325–330, 1988. View at Google Scholar
  36. T. J. Ruescher, A. Sodeifi, S. J. Scrivani, L. B. Kaban, and S. T. Sonis, “The impact of mucositis on α-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies,” Cancer, vol. 82, no. 11, pp. 2275–2281, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. J. H. Kim, C. Goulston, S. Sanders et al., “Cytomegalovirus Reactivation Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Chemotherapeutics and Tandem Transplantation,” Biology of Blood and Marrow Transplantation, vol. 18, no. 11, pp. 1753–1758, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. Y.-H. Kang, B. Seigel, B. Bengsch et al., “CD161+CD4+ T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-γ,” Frontiers in Immunology, vol. 3, article 346, 2012. View at Publisher · View at Google Scholar · View at Scopus